The use of an isopyrine-phenylbutazone compound in migraine.

Abstract

A randomized double-blind study of 40 patients with migraine attacks was carried out to compare an intravenous injection of isopyrine 240 mg plus phenylbutazone 130 mg (Tomanol; Byk-Gulden) with a placebo. Isopyrine is an analgesic with a central sedative action which potentiates the action of phenylbutazone, an inhibitor of prostaglandin biosynthesis and circulation. In 15 patients who received the drug the migraine attack was terminated within 5 minutes of administration, apart from a mild residual headache in 2 cases. No recurrence was reported after 24 hours. The placebo administered to 25 patients gave total relief in 3, a slight improvement of symptoms in 12 and had no effect in 10. Treatment with isopyrine-phenylbutazone compound was based on the immediate central analgesic and sedative action of isopyrine, and the inhibition of the vaso-active action of prostaglandins by phenylbutazone.

• Authors: W Sacks
• Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (S Afr Med J) Vol. 58 Issue 11 Pg. 444-6 (Sep 13 1980) ISSN: 0256-9574 [Print] South Africa
• PMID: 6996149 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Drug Combinations
• Aminopyrine
• isopyrin
• Phenylbutazone

Topics

• Adolescent
• Adult
• Aged
• Aminopyrine (administration & dosage, analogs & derivatives, therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Drug Combinations
• Female
• Humans
• Male
• Middle Aged
• Migraine Disorders (drug therapy)
• Phenylbutazone (administration & dosage, therapeutic use)
• Random Allocation